| Oct 25 |
Iterum stock rallies 54% on FDA approval of Orlynvah for UTIs
|
| Oct 25 |
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
|
| Oct 10 |
Iterum Therapeutics to Present Data at IDWeek 2024
|
| Oct 9 |
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
|
| Sep 24 |
Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship efforts
|
| Sep 10 |
Iterum stock falls 9% in wake of FDA AdComm meeting on UTI drug
|
| Sep 10 |
Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women
|
| Sep 6 |
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
|
| Aug 16 |
Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript
|
| Aug 16 |
When Will Iterum Therapeutics plc (NASDAQ:ITRM) Become Profitable?
|
